ZA202203681B - Compositions and methods for the treatment of viral infections - Google Patents

Compositions and methods for the treatment of viral infections

Info

Publication number
ZA202203681B
ZA202203681B ZA2022/03681A ZA202203681A ZA202203681B ZA 202203681 B ZA202203681 B ZA 202203681B ZA 2022/03681 A ZA2022/03681 A ZA 2022/03681A ZA 202203681 A ZA202203681 A ZA 202203681A ZA 202203681 B ZA202203681 B ZA 202203681B
Authority
ZA
South Africa
Prior art keywords
viral infections
treatment
compositions
methods
binding peptide
Prior art date
Application number
ZA2022/03681A
Other languages
English (en)
Inventor
M Balkovec James
C Bensen Daniel
Borchardt Allen
P Brady Thomas
Chen Zhi-Yong
Cole Jason
Thuy Do Quyen-Quyen
Doehrmann Simon
Jiang Wanlong
Lam Thanh
Noncovich Alain
W Tari Leslie
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of ZA202203681B publication Critical patent/ZA202203681B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2022/03681A 2019-09-06 2022-03-30 Compositions and methods for the treatment of viral infections ZA202203681B (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962897036P 2019-09-06 2019-09-06
US201962941405P 2019-11-27 2019-11-27
US201962948143P 2019-12-13 2019-12-13
US202062959857P 2020-01-10 2020-01-10
US202062966500P 2020-01-27 2020-01-27
US202062970491P 2020-02-05 2020-02-05
US202062984705P 2020-03-03 2020-03-03
US202062988304P 2020-03-11 2020-03-11
US202063032488P 2020-05-29 2020-05-29
US202063062377P 2020-08-06 2020-08-06
PCT/US2020/049772 WO2021046549A1 (en) 2019-09-06 2020-09-08 Compositions and methods for the treatment of viral infections

Publications (1)

Publication Number Publication Date
ZA202203681B true ZA202203681B (en) 2023-11-29

Family

ID=74852729

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/03681A ZA202203681B (en) 2019-09-06 2022-03-30 Compositions and methods for the treatment of viral infections

Country Status (18)

Country Link
US (4) US20210220478A1 (enExample)
EP (1) EP4025256A4 (enExample)
JP (2) JP7667139B2 (enExample)
KR (1) KR20220088527A (enExample)
CN (2) CN114980933B (enExample)
AU (2) AU2020342649B2 (enExample)
CA (1) CA3153359A1 (enExample)
CL (1) CL2022000531A1 (enExample)
CO (1) CO2022003078A2 (enExample)
CR (1) CR20220138A (enExample)
EC (1) ECSP22026797A (enExample)
IL (1) IL290792B1 (enExample)
MX (1) MX2022002728A (enExample)
PE (1) PE20221443A1 (enExample)
PH (1) PH12022550505A1 (enExample)
TW (1) TWI861205B (enExample)
WO (1) WO2021046549A1 (enExample)
ZA (1) ZA202203681B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004266A2 (pt) 2018-09-06 2021-08-03 Cidara Therapeutics, Inc. conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
JP2023511956A (ja) * 2020-01-24 2023-03-23 レゲネロン ファーマシューティカルス，インコーポレーテッド タンパク質－抗ウイルス化合物コンジュゲート
WO2022032188A1 (en) 2020-08-06 2022-02-10 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
US20230364251A1 (en) 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
CA3211494A1 (en) 2021-03-11 2022-09-15 Leslie W. Tari Protein-drug conjugates for antiviral therapy
US20250144220A1 (en) * 2021-12-30 2025-05-08 Suzhou Ark Biopharmaceutical Co., Ltd. Conjugate for preventing and treating viral infections and use thereof
KR20250048157A (ko) * 2022-07-05 2025-04-07 시다라 세라퓨틱스, 인코포레이티드 Cd73의 억제제를 포함하는 fc 컨쥬게이트 및 이의 용도
CN119215189A (zh) 2023-06-29 2024-12-31 上海爱科百发生物医药技术股份有限公司 用于预防和治疗病毒感染的偶联物及其用途
WO2025064869A2 (en) * 2023-09-20 2025-03-27 Cidara Therapeutics, Inc. Compositions and methods for the treatment of cancer
TW202527994A (zh) * 2023-12-08 2025-07-16 大陸商蘇州拓界醫藥有限公司 一種抗病毒偶聯物
WO2025157263A1 (zh) * 2024-01-26 2025-07-31 浙江养生堂天然药物研究所有限公司 偶联物及其制备方法和用途
WO2025230581A1 (en) * 2024-05-02 2025-11-06 Cidara Therapeutics, Inc. Fc conjugates and uses thereof
WO2026055183A1 (en) * 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732916C (en) 1996-11-14 2002-06-06 Biota Scientific Management Pty Ltd Method and novel compounds for use therein
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
SI1196408T1 (en) 1999-06-28 2005-02-28 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
WO2004014316A2 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte, Inc. conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
PT3012258T (pt) 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
MY172021A (en) 2012-10-16 2019-11-12 Janssen Sciences Ireland Uc Rsv antiviral compounds
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
JP6211195B2 (ja) 2013-08-12 2017-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
WO2017046625A1 (en) 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
WO2018006063A1 (en) 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
US20230190950A1 (en) * 2017-01-06 2023-06-22 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
BR112021004266A2 (pt) 2018-09-06 2021-08-03 Cidara Therapeutics, Inc. conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático
WO2020252396A1 (en) 2019-06-13 2020-12-17 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
AU2020291469A1 (en) 2019-06-13 2022-02-10 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
CA3211494A1 (en) * 2021-03-11 2022-09-15 Leslie W. Tari Protein-drug conjugates for antiviral therapy

Also Published As

Publication number Publication date
JP7667139B2 (ja) 2025-04-22
IL290792B1 (en) 2026-04-01
US20260108618A1 (en) 2026-04-23
CN114980933B (zh) 2025-01-07
WO2021046549A1 (en) 2021-03-11
AU2020342649B2 (en) 2025-08-07
PH12022550505A1 (en) 2023-08-23
KR20220088527A (ko) 2022-06-27
US11510992B1 (en) 2022-11-29
NZ785415A (en) 2024-07-26
EP4025256A4 (en) 2023-12-13
WO2021046549A8 (en) 2021-05-20
EP4025256A1 (en) 2022-07-13
US20230398226A1 (en) 2023-12-14
IL290792A (en) 2022-04-01
BR112022004058A2 (pt) 2022-05-31
CA3153359A1 (en) 2021-03-11
CN114980933A (zh) 2022-08-30
US20210220478A1 (en) 2021-07-22
CN120168655A (zh) 2025-06-20
PE20221443A1 (es) 2022-09-21
CR20220138A (es) 2022-07-28
TWI861205B (zh) 2024-11-11
CO2022003078A2 (es) 2022-07-08
MX2022002728A (es) 2022-08-04
AU2020342649A1 (en) 2022-03-24
TW202122117A (zh) 2021-06-16
US12427200B2 (en) 2025-09-30
AU2025263868A1 (en) 2025-11-27
JP2022546609A (ja) 2022-11-04
CL2022000531A1 (es) 2022-10-28
ECSP22026797A (es) 2022-05-31
JP2025108559A (ja) 2025-07-23

Similar Documents

Publication Publication Date Title
PH12021550822A1 (en) Compositions and methods for the treatment of viral infections
ZA202203681B (en) Compositions and methods for the treatment of viral infections
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
CL2018002825A1 (es) Vacuna contra vrs
MX2021003475A (es) Metodos de purificacion de proteinas.
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
MY196095A (en) Antibody That Binds to Envelope Glycoprotein of Severe Fever With Thrombocytopenia Syndrome Virus and use for Same
HK1207829A1 (zh) 疫苗
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
EA202091113A1 (ru) Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
MX391266B (es) Variantes de hppd y metodos de uso.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
BR112013028679A2 (pt) inibidores do vírus da hepatite c
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2020000018A (es) Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
EP4567043A3 (en) Compounds for inducing tissue regeneration and uses thereof
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии